Outpacing Malaria Resistance Through Global Pharma Partnerships
A conversation with Dr. Martin Fitchet, CEO of Medicines for Malaria Venture.
Staying ahead of an evolving parasite requires building next-generation treatments and resilient supply chains long before existing medicines lose effectiveness. In this episode of Outsourcing Against the Outbreak, Dr. Martin Fitchet, CEO of Medicines for Malaria Venture (MMV), discusses how product development partnerships bridge public health priorities with pharma and biotech R&D expertise. The conversation explores the development and regulatory approval of Coartem Baby for newborns under five kilograms, the push to advance novel mechanisms like ganaplacide-lumefantrine ahead of antimalarial resistance, and why MMV teamed up with DNDi on a shared regulatory sciences platform. Dr. Fitchet also details what it takes to establish lasting local GMP manufacturing in Africa through technology transfer, WHO prequalification readiness, and reliable order books.